Urabe Yuji, Ishikawa Hideki, Ishikawa Akira, Ishiguro Shingo, Ishibashi Kazuki, Arihiro Koji, Mutoh Michihiro, Oka Shiro
Department of Gastroenterology, Hiroshima University Hospital, Hiroshima, Japan.
Department of Gastrointestinal Endoscopy and Medicine, Hiroshima University Hospital, Hiroshima, Japan.
Case Rep Gastroenterol. 2024 May 31;18(1):293-298. doi: 10.1159/000538833. eCollection 2024 Jan-Dec.
Familial adenomatous polyposis (FAP), a hereditary disorder of the gastrointestinal tract, is an autosomal dominant inherited condition caused by germline mutations in the adenomatous polyposis coli () gene. It is characterized by the development of hundreds to thousands of colorectal adenomatous polyps, which, if left untreated, can eventually develop into colorectal carcinomas. Representative extracolonic tumors in FAP include multiple duodenal adenomas and desmoid tumors. Moreover, multiple fundic gland polyps are frequently identified in the stomachs of patients with FAP.
Herein, we report the two cases. A 52-year-old woman who underwent total colectomy for FAP, and pancreatoduodenectomy was initiated on esomeprazole for the treatment of anastomotic erosion. Esophagogastroduodenoscopy performed 42 months later showed an increased number and size of gastric fundic gland polyps, which subsequently decreased after replacing esomeprazole with ranitidine. Similarly, a 39-year-old woman with FAP was initiated on vonoprazan for the treatment of reflux symptoms. Esophagogastroduodenoscopy and colonoscopy performed 14 months later indicated an increase in the number of gastric fundic gland polyps and colorectal polyps, which subsequently decreased after vonoprazan discontinuation. In these two cases, the increase and decrease in the number and size of fundic gland polyps and colon adenoma were associated with serum gastrin levels.
Gastric fundic gland polyps and colon polyps may rapidly increase in number and size due to increased gastrin levels induced by proton pump inhibitor/potassium-competitive acid blocker use. Hence, these drugs should be prescribed with caution.
家族性腺瘤性息肉病(FAP)是一种胃肠道遗传性疾病,是由腺瘤性息肉病 coli()基因的种系突变引起的常染色体显性遗传疾病。其特征是发展出数百至数千个结肠直肠腺瘤性息肉,如果不进行治疗,最终可能发展为结肠直肠癌。FAP 中典型的结肠外肿瘤包括多个十二指肠腺瘤和硬纤维瘤。此外,在 FAP 患者的胃中经常发现多个胃底腺息肉。
在此,我们报告两例病例。一名 52 岁女性因 FAP 接受了全结肠切除术,因吻合口糜烂开始使用埃索美拉唑进行治疗。42 个月后进行的食管胃十二指肠镜检查显示胃底腺息肉的数量和大小增加,在用雷尼替丁替代埃索美拉唑后息肉数量和大小随后减少。同样,一名 39 岁患有 FAP 的女性因反流症状开始使用沃克(vonoprazan)进行治疗。14 个月后进行的食管胃十二指肠镜检查和结肠镜检查显示胃底腺息肉和结肠息肉的数量增加,在停用沃克后息肉数量随后减少。在这两例病例中,胃底腺息肉和结肠腺瘤的数量和大小的增加和减少与血清胃泌素水平相关。
由于使用质子泵抑制剂/钾竞争性酸阻滞剂导致胃泌素水平升高,胃底腺息肉和结肠息肉的数量和大小可能会迅速增加。因此,应谨慎使用这些药物。